BioSpace News Archive

The global 3D printed implants market is an important part of the growing larger trend, the 3D printing in medical applications.

Sage Therapeutics to Present at Morgan Stanley 18 th Annual Global Healthcare Conference

80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus eight days in control group Lenzilumab patients discharged from the hospital in less than half the time compared with control group BURLINGAME, Cali

Various Atara Posters Being Presented at ACTRIMS-ECTRIMS Further Elucidate the Role of EBV in MS Company to Host Live Conference Call and Webcast to Review MS Data Presentation on Friday, September 11, 2020 at 8:30 a.m. ET/5:30 p.m. CEST SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for pa

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle ® -based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema CAMBRIDGE, England & BOSTON--( BUSINESS WIRE )-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has received confirmation from the Canadian Stock Exchange (the “Exchange”) that its common shares will resume trading on Tuesday, September 1, 2020. Trading on the OTC is expected to resume shortly thereafter. The Exchange’s Listing Committee has approved Betterlife’s new Listing Statement after having received satisfactor

Hepion Pharmaceuticals, Inc. today announced that CRV431 dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose (“MAD”) study of CRV431

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that it has entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank (SVB).

Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced key appointments to its business and clinical development teams. Mark J. Gilbert, M.D., a cell therapy pioneer, joins as senior vice president of Research and Development and will lead early-stage research efforts to advance the company’s proprietary, potent and off-the-shelf cell therapies from exploratory development stages into clinical trials.

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that applications to the Turkish Ministry of Health and local Ethics Committee have been submitted to obtain permission to recruit COVID-19 patients in Turkey for the Phase II trial of its lead drug, LSALT peptide (Metablok).